Ajax Therapeutics

Targeting cancer through precise selectivity

New York, United States · Founded 2019 · $143.0M raised

Headquarters
New York, New York
Employees
1–10
Founded
2019
Business Model
B2B
Total Funding
$143.0M
Last Round
$8.0M Series AMay 2024
Rounds
3

About

Ajax Therapeutics is a clinical-stage biotechnology company applying computational chemistry and structural biology to develop next-generation JAK2 inhibitors for myeloproliferative neoplasms (MPNs). Their lead candidate, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical trials for myelofibrosis. The company has raised $143M from investors including Goldman Sachs, Eli Lilly, and RA Capital Management.

Summary

Ajax Therapeutics is a Biotech company based in New York, United States, founded in 2019. It has raised $143.0M in total across 3 rounds, most recently a $8.0M Series A round in May 2024. Investors include EcoR1 Capital, OrbiMed and Goldman Sachs Alternatives.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CMay 2024
$95.0M

Sign up to see all 3 rounds

Series A through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ajax Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/ajax-therapeutics"><img src="https://indexed.vc/api/badge/company/ajax-therapeutics" alt="Ajax Therapeutics on Indexed.vc" width="260" height="76" /></a>